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Plasma adiponectin levels and 
type 2 diabetes risk: a nested 
case-control study in a Chinese 
population and an updated meta-
analysis
Yeli Wang1, Rui-Wei Meng2, Setor K. Kunutsor3, Rajiv Chowdhury4, Jian-Min Yuan5,6,  
Woon-Puay Koh1,7 & An Pan2
Results from previous prospective studies assessing the relation between adiponectin and type 2 
diabetes (T2D) were not entirely consistent, and evidence in Chinese population is scarce. Moreover, 
the last meta-analysis did not examine the impact of metabolic variables on the adiponectin-T2D 
association. Therefore, we prospectively evaluated the adiponectin-T2D association among 571 T2D 
cases and 571 age-sex-matched controls nested within the Singapore Chinese Health Study (SCHS). 
Furthermore, we conducted an updated meta-analysis by searching prospective studies on Pubmed 
till September 2016. In the SCHS, the odds ratio of T2D, comparing the highest versus lowest tertile 
of adiponectin levels, was 0.30 (95% confidence interval: 0.17, 0.55) in the fully-adjusted model. 
The relation was stronger among heavier participants (body mass index ≥23 kg/m2) compared to 
their leaner counterparts (P for interaction = 0.041). In a meta-analysis of 34 prospective studies, the 
pooled relative risk was 0.53 (95% confidence interval: 0.47, 0.61) comparing the extreme tertiles of 
adiponectin with moderate heterogeneity (I2 = 48.7%, P = 0.001). The adiponectin-T2D association 
remained unchanged after adjusting for inflammation and dyslipidemia markers, but substantially 
attenuated with adjustment for insulin sensitivity and/or glycaemia markers. Overall evidence indicates 
that higher adiponectin levels are associated with decreased T2D risk in Chinese and other populations.
Adiponectin, a major adipokine secreted by adipose tissue1, has attracted much attention due to its anti- 
inflammatory and insulin-sensitizing properties as well as its beneficial role in glucose metabolism2. Animal 
studies and experimental studies have shown that adiponectin improves insulin sensitivity3,4, thus may prevent 
the development of type 2 diabetes (T2D). A meta-analysis in year 2009 summarized data from 13 prospec-
tive studies in various populations, and confirmed an inverse association between adiponectin levels and T2D 
risk5, since then, many more studies have been published with variability in the strength of the adiponectin-T2D 
association6–23. Most of the previous studies have been conducted in the Western populations, and a few were 
conducted among Asian populations such as Japanese, Indians and Koreans. Chinese have lower adiponectin 
levels compared to other ethnic groups24. Meanwhile, Chinese are also particularly sensitive to the detrimental 
metabolic effects of greater body fatness25. So far only a relatively small study (76 T2D cases) has examined the 
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association between adiponectin levels (binary variable) and T2D risk in a Hong Kong Chinese population in 
the context of T2D prediction model26. However, the shape of the association, and its potential confounders or 
modifying factors are unclear in a Chinese population.
The results from previous studies on the adiponectin-T2D relationship have not been entirely consistent. 
While some studies have reported a non-linear association13,27, others have observed a linear relationship5,21. 
Furthermore, data were conflicting on whether the association was modified by gender10,13,15,17,28–31 or levels of 
obesity13,22,27,30,32, and whether adiponectin improved T2D prediction significantly6,16,26,33–37. Moreover, the last 
meta-analysis pooled risk estimates from models that did not adjust for metabolic variables such as lipids, mark-
ers of inflammation, glycaemia and insulin sensitivity5.
In this context, we first conducted a case-control study nested within the prospective, population-based 
cohort, the Singapore Chinese Health Study (SCHS), to quantify the association between plasma adiponectin lev-
els and risk of incident T2D in a Chinese population. We adjusted for blood lipids, inflammatory biomarker, glu-
cose and insulin levels in the multivariable models to further test the potential mediation effect. We also assessed 
the incremental value of adiponectin in T2D risk prediction over established risk factors in this population. We 
further conducted an updated meta-analysis of published reports on circulating adiponectin and T2D, involving 
another 33 population-based longitudinal studies. We performed comprehensive stratified analysis to explore the 
heterogeneity among different subgroups and examined the dose-response relationship between adiponectin and 
T2D risk in the updated meta-analysis.
Results
Results in the SCHS. The process of selecting participants from SCHS in this study is presented in 
Supplemental Figure S1. The baseline characteristics of cases and controls are shown in Table 1. The mean age 
(standard deviation [SD]) of the participants was 59.7 (6.2) years and 58.7% were females. As expected, cases had 
high-risk profiles except for the matching factors, including higher body mass index (BMI) and higher prevalence 
of hypertension. No significant differences were found for education levels, smoking status, alcohol consumption 
and physical activity levels. For the plasma biomarkers, cases had higher levels of hemoglobin A1c (HbA1c), 
high-sensitivity C-reactive protein (hs-CRP), random glucose, random insulin, triglycerides (TG), and the ratio 
of TG to HDL-cholesterol (HDL-C), but lower HDL-C levels. The median (interquartile) concentration of adi-
ponectin was 6.7 (5.2–8.3) µg/mL in men and 8.1 (6.4–10.5) µg/mL in women, and it was 6.7 (5.2–8.3) µg/mL in 
the cases and 8.4 (6.5–10.8) µg/mL in the controls.
Among the healthy control subjects, plasma adiponectin levels were inversely correlated with BMI, hs-CRP, 
random insulin, TG and the ratio of TG to HDL-C (Pearson’s coefficient r = −0.15, −0.19, −0.20, −0.43, and 
−0.50, respectively; all P < 0.001), and positively correlated with age and plasma HDL-C level (Pearson’s coeffi-
cient r = 0.11, and 0.49, P < 0.01) (Supplemental Table S1).
The association between adiponectin and risk of T2D is presented in Table 2. In the model with adjust-
ment for T2D risk factors, higher plasma adiponectin levels were associated with a lower T2D risk, and the 
odds ratio (OR) and 95% confidence interval (CI) comparing the highest vs. lowest tertiles was 0.19 (0.12, 0.30; 
P-trend < 0.001). The association was slightly attenuated after adjusting for hs-CRP, and the ratio of TG to HDL-C 
(OR 0.31; 95% CI: 0.20, 0.51; P-trend < 0.001), and random glucose and insulin levels (OR 0.30; 95% CI: 0.17, 
0.55; P-trend < 0.001). Moreover, significant associations were found in 292 case-control pairs with the cases hav-
ing baseline HbA1c < 6.5% (48 mmol/mol) at the time of blood-taking, as well as in 279 case-control pairs with 
the cases having baseline HbA1c ≥6.5% (48 mmol/mol). In addition, the adiponectin-T2D association remained 
significant among 146 case-control pairs with HbA1c < 6.0% (42 mmol/mol). Significant interaction was found 
with BMI status (P for interaction = 0.041; Supplemental Table S2), and the association was stronger among over-
weight/obese subjects (BMI ≥23.0 kg/m2) than lean conterparts (BMI < 23.0 kg/m2). No statistically significant 
interactions were found with other variables.
The summary statistics for the predictive performance of adiponectin is presented in the Supplemental Tables S3 
and S4. The area under the receiver operating characteristic curve (AUC) for base model 1, which included educa-
tion level, physical activity, history of hypertension, BMI, TG, HDL-C, and hs-CRP, was 0.74 (95% CI: 0.71, 0.77). 
Addition of adiponectin showed statistically significant improvement in AUC (AUC change = 0.02, P < 0.05), reclas-
sified 33% individuals more appropriately (net reclassification improvement [NRI] = 0.33, P < 0.001) and led to 
an integrated discrimination improvement (IDI) of 0.03 (P < 0.001). Base model 2, with additional inclusion of 
random glucose and insulin levels, had an AUC of 0.82 (95% CI: 0.80, 0.85). Adding adiponectin did not improve 
AUC significantly, but resulted in statistical significant NRI (0.19, P = 0.003) and IDI (0.01, P < 0.001), indicating 
that the difference in average predicted risks between individuals with and without T2D increased significantly 
when adiponectin was included in the prediction model. Base model 3, substituting random glucose in base model 2 
with HbA1c, had an AUC of 0.87 (95% CI: 0.84, 0.89), which was significantly higher than the AUC of base model 2 
(AUC change = 0.05, P < 0.001). Similar to base model 2, adding adiponectin to base model 3 did not improve AUC, 
but resulted in small yet marginally significant NRI (0.12, P = 0.051) and IDI (0.01, P < 0.05).
Meta-analysis. Our initial search identified 2159 potentially relevant citations (Supplemental Figure S2). 
After screening for title, abstract and full texts, we included 33 prospective cohort studies based on 31 articles (2 
articles reported results for 4 cohort studies), and the characteristics of the studies are shown in the Tables 3–4. 
Eighteen studies included participants from Europe, 9 studies from North America, and 6 studies from Asia. 
There were 7504 T2D cases among 64,696 participants including our study. The duration of follow-ups varied 
from 1 to 18 years, the mean ages ranged from 26.5 to 74.8 years. Four studies were conducted in men only19,23,32,38, 
and two studies were in women only9,27, while 28 studies were in both sexes, among which five studies provided 
risk estimates for men and women separately7,10,15,17,28. Furthermore, study qualities ranged from 5 to 9 (Table 3).
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The pooled relative risk (RR) comparing the highest to lowest tertile of adiponectin concentrations was 
0.53 (95% CI: 0.47, 0.61) using the random-effects model (Figure 1), and results were similar when using the 
fixed-effects model (RR 0.54; 95% CI: 0.50, 0.59). A moderate heterogeneity was observed (I2 = 48.7%; P = 0.001), 
and the meta-regression analysis suggested evidence of effect modification by level of adjustment (P = 0.08) (data 
not shown). We further performed stratified analysis by level of adjustment, and the association was attenuated 
after further adjustment for glycaemia markers and/or insulin sensitivity markers, while additional adjustment 
for lipids and/or inflammatory markers did not materially change the association (Supplemental Table S5). When 
stratifying by baseline participant characteristics, the inverse association was consistently observed among all 
subgroups (Supplemental Table S5).
Twelve studies (14 data points because two studies reported results for men and women separately10,28) pro-
vided data for dose-response meta-analysis (Supplemental Table S6). Cubic spline regression model suggested a 
linear dose-response relationship (P = 0.33 for nonlinearity) (Figure 2). The RRs of T2D with per 5 µg/mL incre-
ment in adiponectin levels were 0.75 (95% CI: 0.73, 0.77) in the random-effects model. No significant publication 
bias was detected (P = 0.12 in the Egger’s test).
Discussion
In this nested case-control study, we found a strong dose-dependent association between higher plasma adi-
ponectin levels and lower T2D risk, which seemed to be independent of established T2D risk factors, including 
lipids, inflammatory biomarker (hs-CRP), random glucose and insulin. Moreover, the inverse association was 
Cases (n = 571) Controls (n = 571) P-valueb
Age (years) at blood taken 59.6 (6.1) 59.7 (6.2) —
Gender (Female) 335 (58.7) 335 (58.7) —
Dialect (%) —
Cantonese 287 (50.3) 287 (50.3)
Hokkien 284 (49.7) 284 (49.7)
Body mass index, kg/m2 24.8 (3.6) 22.8 (3.3) <0.001
Level of education (%) 0.15
No formal education 104 (18.2) 99 (17.3)
Primary school 255 (44.7) 233 (40.8)
Secondary and above 212 (37.1) 239 (41.9)
History of Hypertension (%) 265 (46.4) 148 (25.9) <0.001
Cigarette smoking (%) 0.08
Never smokers 410 (71.8) 425 (74.4)
Former smoker 63 (11.0) 71 (12.4)
Current smokers 98 (17.2) 75 (13.1)
Weekly moderate-to-vigorous activity (%) 0.37
<0.5 hour/week 456 (79.9) 454 (79.5)
0.5–3.9 hours/week 82 (14.4) 68 (11.9)
≥4.0 hours/week 33 (5.8) 49 (8.6)
Alcohol Intake (%) 0.89
Abstainers 498 (87.2) 497 (87.0)
Weekly drinkers 55 (9.6) 59 (10.3)
Daily drinkers 18 (3.2) 15 (2.6)
Fasting status (yes) 178 (31.2) 156 (27.3) 0.15
Adiponectin, µg/mL 6.7 (5.2–8.3) 8.4 (6.5–10.8) <0.001
High-sensitivity C-reactive protein, mg/L 1.8 (1.0–3.5) 1.2 (0.6–2.3) <0.001
Random glucose, mmol/L 6.0 (4.8–8.9) 4.5 (4.1–5.3) <0.001
Random insulin, mIU/L 14.7 (7.9–35.2) 9.0 (4.5–22.0) <0.001
Total cholesterol, mmol/L 5.31 (0.95) 5.20 (0.85) 0.05
HDL cholesterol, mmol/L 1.08 (0.24) 1.23 (0.32) <0.001
Triglycerides, mmol/L 2.2 (1.5–3.0) 1.5 (1.1–2.2) <0.001
Ratio of triglycerides to HDL cholesterol 1.3 (0.8–2.1) 2.0 (1.3–3.0) <0.001
Hemoglobin A1c, % 6.83 (1.44) 5.55 (0.27) <0.001
Hemoglobin A1c, mmol/mol 51 38 <0.001
Table 1. Baseline characteristics of cases and controls, case-control study nested within Singapore Chinese 
Health Studya. aData are expressed as mean (SD) for continuous variables with normal distribution, median 
(interquartile range) for continuous variables with skewed distribution, and n (percentage) for categorical 
variables. Cases and controls are matched on age at blood taken (±3 years), gender, dialect, and date of blood 
collection ( ± 6 months). bP-values were based on conditional logistic regression.
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significantly stronger among overweight/obese subjects than their lean counterparts. Furthermore, adiponectin 
significantly improved T2D risk reclassification in this population. In an updated meta-analysis which pooled 
data from 34 prospective studies including the current study, participants in the highest tertile had almost 
half the risk of developing T2D compared to those in the lowest tertile (RR 0.53; 95% CI: 0.47, 0.61), and the 
adiponectin-T2D association appeared to be linear.
A previous meta-analysis of 13 prospective studies (2623 incident T2D cases and 14,598 participants) reported 
an inverse association between adiponectin levels and T2D risk (RR 0.72 for per 1-log µg/mL increment in adi-
ponectin levels) across different populations5, but no study was done in Chinese population. In the current study, 
we not only observed the inverse association in a Chinese population after comprehensive adjustment, but also 
conducted an updated meta-analysis with a much larger sample size (7504 incident T2D cases and 64,696 par-
ticipants), which provided strong evidence for the role of adiponectin in the pathogenesis of T2D across diverse 
populations, a consistent finding despite methodologic variations such as adiponectin assays, diagnostic criteria 
for T2D and follow-up durations.
Several lines of evidence have hypothesized that adiponectin may act against T2D development by lowering 
blood glucose through improving insulin sensitivity. Mechanistic studies have shown that adiponectin improves 
insulin sensitivity by stimulating glucose utilization and fatty acid oxidation in the skeletal muscle and liver 
through improving AMP-activated protein kinase4. Animal studies have shown that adiponectin levels drop in 
parallel with reduced insulin sensitivity, before the increment in glycemic levels3. A recent Mendelian random-
ization study in humans provided further evidence between increased adiponectin levels and improved insulin 
sensitivity using ADIPOQ SNPs as instruments39. Additionally, we found in our current meta-analysis that the 
adiponectin-T2D association was substantially attenuated in studies that adjusted for insulin sensitivity and/or 
glycaemia markers compared to studies that did not adjust for either one of them, suggesting that the association 
was at least partially mediated through insulin and glucose pathways. Moreover, the stratified analysis from the 
current meta-analysis suggested that lower adiponectin levels may contribute to an increased T2D risk through 
pathways independent of other important T2D pathogenic mechanisms such as dyslipidemia and inflammation. 
Although adiponectin is an adipose-specific protein and its concentration reduces with increasing level of obe-
sity40, the current cohort study together with previous studies10,11,22 have shown that adjustment for markers of 
Tertiles of adiponectin concentrations
P for trenda per 1 log µg/mLT1 T2 T3
Whole dataset
Median (range) 5.5 (1.4, 7.1) 8.3 (7.2, 9.8) 11.8 (9.9, 29.9)
Cases/controls 328/191 173/191 70/189
Model 1b 1.00 0.55 (0.40, 0.76) 0.19 (0.12, 0.30) <0.001 0.16 (0.10, 0.25)
Model 2c 1.00 0.67 (0.48, 0.95) 0.31 (0.20, 0.51) <0.001 0.26 (0.16, 0.42)
Model 3d 1.00 0.80 (0.52, 1.23) 0.30 (0.17, 0.55) <0.001 0.26 (0.14, 0.48)
Limited to cases with baseline hemoglobin A1c ≥ 6.5% (48 mmol/mol) and their matched controls
Median (range) 5.5 (1.4, 7.0) 8.1 (7.1, 9.7) 11.8 (9.8, 29.9)
Cases/controls 159/98 88/92 32/89
Model 1b 1.00 0.63 (0.41, 0.99) 0.19 (0.10, 0.37) <0.001 0.13 (0.07, 0.25)
Model 2c 1.00 0.86 (0.53, 1.38) 0.35 (0.17, 0.71) 0.01 0.22 (0.11, 0.44)
Model 3d 1.00 2.08 (0.87, 4.98) 0.27 (0.08, 0.90) 0.20 0.26 (0.09, 0.82)
Limited to cases with baseline hemoglobin A1c < 6.5% (48 mmol/mol) and all the controls
Median (range) 5.7 (2.1, 7.5) 8.7 (7.6, 10.0) 12.1 (10.1, 26.7)
Cases/controls 185/101 71/96 36/95
Model 1b 1.00 0.38 (0.23, 0.62) 0.18 (0.09, 0.33) <0.001 0.18 (0.10, 0.34)
Model 2c 1.00 0.47 (0.28, 0.80) 0.29 (0.15, 0.58) <0.001 0.32 (0.16, 0.63)
Model 3d 1.00 0.57 (0.32, 1.04) 0.32 (0.14, 0.70) 0.003 0.32 (0.15, 0.70)
Limited to cases with baseline hemoglobin A1c < 6.0% (42 mmol/mol) and all the controls
Median (range) 5.9 (2.2, 7.5) 8.7 (7.6, 10.0) 12.2 (10.1, 26.7)
Cases/controls 78/49 47/50 21/47
Model 1b 1.00 0.56 (0.29, 1.09) 0.21 (0.09, 0.49) <0.001 0.25 (0.11, 0.56)
Model 2c 1.00 0.79 (0.38, 1.63) 0.36 (0.14, 0.90) 0.037 0.44 (0.17, 1.10)
Model 3d 1.00 0.77 (0.34, 1.77) 0.34 (0.12, 0.98) 0.06 0.40 (0.14, 1.19)
Table 2. Odds ratios (95% confidence intervals) for risk of type 2 diabetes according to tertiles of adiponectin, 
the Singapore Chinese Health Study. aLinear trend was tested by using the median level of each tertile of 
adiponectin. bModel 1: adjusted for age at blood taken (continuous), smoking (never, ever smoker), alcohol 
intake (never, ever drinker), weekly moderate-to-vigorous activity (<0.5, ≥0.5 hours/week), education level 
(primary school and below, secondary or above), history of hypertension (yes, no), fasting status (yes, no), and 
body mass index (continuous); cModel 2: Model 1 plus adjusted for high-sensitivity C-reactive protein, and the 
ratio of triglycerides to high-density lipoprotein cholesterol (both in tertiles). dModel 3: Model 2 plus adjusted 
for random glucose and random insulin (both in tertiles).
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Reference, Year
Study name or source of 
participants
Study 
location
Study  
design
Follow-
up 
years
Mean 
baseline 
age or 
range
Female 
(%)
Number of 
cases/non-
cases Adiponectin assay
Ascertainment of type 2 
diabetes
Study 
quality
Lindsay et al.57 Gila River Indian Community USA Nested case-control 6.7 32 66 70/70 ELISA OGTT 7
Daimon et al.58 Funagata study Japan Cohort 5 58 58 18/819 ELISA OGTT 7
Snehalatha 
et al.59
Indian Diabetes Prevention 
Program India Cohort 1 45 42 25/66 RIA OGTT 5
Choi et al.60 South-West Seoul Korea Cohort 3 70 NA 25/294 RIA OGTT 6
Kanaya et al.61 Health ABC USA Cohort 5 74 53 143/2213 RIA (1) self-report; (2) medication intake; (3) OGTT 8
Koenig et al.38 MONICA Ausburg Germany Cohort 18 54 0 115/772 ELISA confirmed self-report 6
Nakashima 
et al.62
Hawaii-Los Angeles-Hiroshima 
Study USA Cohort 5.4 61.3 58 112/654 ELISA OGTT 7
Snijder et al.28 The Hoorn Study Netherlands Cohort 6.4 60 54 118/1146 Latex turbidimetric immunoassay OGTT 8
Wannamethee 
et al.32 British Regional Heart Study UK Cohort 5 69 0 105/3462 ELISA Confirmed self-report 7
Heidermann 
et al.27 Nurses’ Health Study USA
Nested case-
control 12 56 100 1038/1136 ELISA Confirmed self-report 7
Ley et al.63 Sandy Lake Health and Diabetes Project cohort Canada Cohort 10 27 58 86/406 RIA
(1) self-report; (2) medication 
intake; (3) OGTT 8
Mather et al.31 Diabetes Prevention Program USA Cohort 1 51 68 115/925 Latex turbidimetric immunoassay OGTT 5
Tábak et al.64 Whitehall II Study UK Nested case-control 11.5 51 31 55/85
Bio-Plex Suspension 
assay
(1) self-report; (2) medication 
intake; (3) OGTT 8
Salomaa et al.6 FINRISK97 Finland Cohort 10.8 46 50 417/7410 ELISA (1) medication; (2) hospital record and death registry 8
Health 2000 cohort Finland Cohort 7.1 53 54 179/4798 ELISA (1) medication; (2) hospital record and death registry 8
Thorand et al.7 MONICA/KORA Germany Case-cohort 10.9 53 49 460/1474 ELISA Confirmed self-report 8
Zhu et al.8 ARIC USA Case-cohort 9 45–64 63 550/540 ELISA (1) Physician diagnosis; (2) medication use; (3) OGTT 9
Fagerberg et al.9 population-based cohort of 64-year-old women Sweden Cohort 5.5 70 100 69/272 ELISA OGTT 9
Hanley et al.10 IRAS Family Study USA Cohort 5 41 61 82/1014 RIA (1) OGTT; (2) medication use 8
Hivert et al.11 KORA S4/F4 Germany Cohort 8 63 49 93/794 RIA (1) Physician diagnosis; (2) OGTT 8
Framingham Offspring Study USA Cohort 6.5 60 56 109/1914 ELISA (1) OGTT; (2) medication use 8
Montonen et al.12 EPIC-Potsdam Germany Case-cohort 7 51 58 613/1965 ELISA Confirmed self-report 7
Kizer et al.13 Cardiovascular Health Study USA Cohort 10.6 75 63 309/3493 ELISA (1) use of medication; (2) OGTT 8
Li et al.14 local government workers from Aichi perfecture Japan Cohort 5.3 47 23 164/2844 ELISA (1) OGTT; (2) self-report 9
Lilja et al.15 Västerbotten Intervention Program Sweden
Case-
referent 17 53 48 640/1564 double antibody RIAs OGTT 9
Marques-Vidal 
et al.16 The CoLaus Study Switzerland Cohort 5.5 52 57 208/3634 ELISA
(1) OGTT; (2) presence of oral 
hypoglycaemic; (3) insulin 
treatment
9
Kim et al.17 Seuol Metabolic Syndrome Research Initiatives Korea Cohort 4.4 46 20 652/4433 ELISA
(1) OGTT; (2) 3 outpatient 
treatment; (3) hospitalization 
due to type 2 diabetes
7
Rubio-Martin 
et al.18 Pizarra cohort study Spain Cohort 5 44 65 52/417 EIA OGTT 8
Sans et al.19 MONICA-Catalonia Spain Cohort 9.4 50 0 85/799 Luminex xMAP technology (1) OGTT; (2) self-report 8
Julia et al.20 SU.VI.MAX study France Nested case-control 13 51 51 82/1263 ELISA (1) OGTT; (2) medication 9
Lindberg et al.21 Patients with Myocardial infarction Denmark Cohort 5.7 64 26 38/628
Immunoturbidimetric 
assay
Registry, validated using 
medical records 7
Yamamoto et al.22 Hitachi Health Study Japan Cohort 3 52 10 214/4377 Immunoturbidimetric assay
(1) OGTT; (2) HbA1c ≥6.5%; 
(3) under diabetes treatment 9
Neville et al.23 PRIME study Ireland Cohort 14.7 55 0 151/1688 ELISA Confirmed self-report 8
Table 3. Baseline characteristics of the 33 prospective studies included in the meta-analysis Abbreviations: 
Health ABC, Health, Aging and Body Composition; MONICA, MONIotring of trends and determinants 
in CArdiovascular disease; KORA, Cooperative Health Research in the Region of Augsburg; ARIC, The 
Atherosclerosis Risk in Communities Study; IRAS, The insulin resistance atherosclerosis study; EPIC, 
The European Prospective Investigation into Cancer and Nutrition study; SU.VI.MAX, SUpplementation 
en VItamines et Mineraux AntioXydants; PRIME, The Prospective Epidemiological Study of Myocardial 
Infarction; RIA, radioimmunoassays; EIA, enzyme immunoassay.
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obesity, such as BMI or CT-assessed abdominal fat area, did not materially change the association between adi-
ponectin and T2D risk, suggesting that low adiponectin levels could be associated with higher T2D risk through 
pathways that may not be related to systemic or regional fat deposition.
Moreover, our study found stronger relation of adiponectin with T2D risk in overweight/obese people than 
their leaner counterparts. In line with our results, a 4-year follow-up study of elderly British men found stronger 
association among obese participants (BMI ≥30.0 kg/m2) than non-obese counterparts32. Similarly, a Japanese 
cohort study reported stronger association in overweight/obese individuals (BMI ≥25.0 kg/m2) than in normal 
weight people22. Some other studies also found that the association between adiponectin levels and T2D were 
stronger in participants with higher metabolic risk profile11,17,41. A recent Mendelian randomization study in 
a Swedish population also observed a stronger causal relation between adiponectin and insulin sensitivity in 
participants with higher BMI39. Although the underlying mechanism for the observed interaction with obesity 
is still unclear, the Mendelian randomization study hypothesized that the observed interaction with BMI may be 
due to the interaction between adiposity and the ADIPOQ SNPs, in which the transcription factors could have 
been regulated by the inflammatory mediators to stimulate the binding site and thus cause up-regulation of the 
related gene39. However, given the multiple statistical tests for interaction conducted and that some studies did 
not observe significant interactions with BMI13,27,30, our observed interaction with BMI should be interpreted 
with caution.
In the current study, adding adiponectin beyond traditional risk factors and glucose markers (random glucose 
or HbA1c) did not improve discrimination (assessed by AUC), but improved risk reclassification (assessed by 
NRI and IDI) for T2D. In consistent with our results, two cohort studies from Switzerland and Germany did not 
observe significant improvement in AUC when adding adiponectin alone to base models that included fasting 
glucose16,34. In contrast, results from a cohort in Hong Kong and EPIC-Potsdam study have shown that adiponec-
tin improved AUC significantly beyond glucose markers26,37, and interestingly, in a previous study conducted in 
Finland, adiponectin improved AUC and NRI significantly in the primary cohort (FINRISK97) but not in the 
validation cohort (Health 2000)6. In addition, a T2D score comprising adiponectin and other five biomarkers has 
shown better predictive utility (assessed by AUC) than HbA1c and fasting glucose in a Danish population33, and 
the predictive utility of the score was further validated in two cohorts from Finland35 and US36 using AUC and 
NRI.
Our study has several strengths. First, we have adjusted for well-established T2D factors and used compre-
hensive statistical methods to explore the predictive utility of adiponectin. Moreover, compared to the previous 
meta-analysis5, our updated meta-analysis included more prospective studies with a tripled sample size; we have 
also included results from models that have adjusted for a comprehensive panel of T2D biomarkers (lipids and 
markers of inflammation, glycaemia and insulin sensitivity) to examine their impact on the adiponectin-T2D 
association, and further performed stratified analysis by these factors to explore potential heterogeneity among 
subgroups. Furthermore, we have performed a dose-response meta-analysis among 12 studies, and observed a lin-
ear association between adiponectin and T2D. However, the current study has some limitations as well. First, we 
measured adiponectin levels only once and some measurement errors are inevitable. In addition, the height and 
weight were self-reported and residual confounding was possible. Hence, this could lead to non-differential mis-
classifications and result in an underestimation of the true effect size of adiponectin on T2D risk. Furthermore, 
information of more precise surrogates for insulin resistance (such as fasting insulin, HOMA-IR, and insulin 
sensitivity index) and glycaemia markers (such as fasting glucose) were not available in the study, thus, random 
insulin and glucose levels were used as covariates in our models. Moreover, incident T2D was obtained from 
self-reported information, thus undiagnosed T2D may exist. However, we have used HbA1c as a selection crite-
rion (<6.0%) for controls to minimize bias due to undiagnosed T2D. In addition, we also conducted sensitivity 
analysis restricting to cases with HbA1c <6.5% and <6.0% at the time of blood collection and their respective 
controls, and observed similar adiponectin-T2D association. Furthermore, the present study was conducted in 
a middle-aged and elderly population with a higher T2D incidence and adiponectin levels, and the findings may 
not be applicable to younger age group28. However, in the current meta-analysis, we did not observe any hetero-
geneity of results by age group, suggesting the finding will be most likely to be observed in younger people as well.
Materials and Methods
Study population. The design of the SCHS was described in detail previously42. Briefly, the SCHS was estab-
lished between 1993 and 1998, and recruited 63,257 Chinese adults aged 45–74 years. At recruitment, an in-per-
son interview was conducted using a structured questionnaire to collect information of diet, lifestyle habits and 
medical history. Follow-up I interviews were conducted via telephone between 1999 and 2004 to update selected 
lifestyle habit and medical history. A total of 52,322 participants were re-contacted successfully, and among them, 
a total of 32,535 participants donated their bio-specimens during follow-up I visits. Follow-up II interviews were 
conducted via telephone from 2006 to 2010, and 39,528 participants were re-contacted successfully. Among the 
32,535 participants who donated bio-specimens, 25,477 (78.3%) were re-contacted for follow-up II interviews. 
The study protocol was approved by the Institutional Review Boards at the National University of Singapore and 
the University of Pittsburgh, and all methods were performed in accordance with the relevant guidelines and 
regulations. Informed consent was provided with completion of the baseline interview.
Ascertainment of diabetes and other covariates. History of physician-diagnosed diabetes was asked 
at baseline and both follow-up interviews using the question: “Have you been told by a doctor that you have 
diabetes?” If the answer was “yes”, participants were also asked for the age at which they were first diagnosed. 
The robustness and accuracy of the self-reported diabetes data has been confirmed in a validation study: among 
1651 cohort participants who reported history of diabetes either at baseline or follow-up I interview, 98.9% were 
confirmed by medical records or telephone interview. Some participants (n = 619) refused or were not available 
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Reference, Year Comparison Model RR 95% CI Adjustment for covariates
Lindsay et al.57 Per SD increment Multivariable 0.59 0.38, 0.91 Age, waist circumference, fasting and 2-h glucose, fasting insulin. Matched for BMI, age and sex
Daimon et al.58 Highest tertile (median, 13.9 μg/mL) vs lowest (4.7 μg/mL) Multivariable 0.11 0.01, 0.96 Age, sex, waist-hip ratio, 2-h glucose, TNF-1
Snehalatha et al.59 Per 1 μg/mL increment Multivariable 0.87 0.79, 0.95 HbA1c
Choi et al.60 Highest tertile (median, 23.8 μg/mL) vs lowest (7.9 μg/mL) Multivariable 0.31 0.14, 0.71 BMI
Kanaya et al.61 per 1 log μg/mL Multivariable 1.04 0.69, 1.56 Age, sex, race, BMI, visceral fat, hypertension, leptin, PAI-1, fasting glucose and insulin, HDL-C, TG
Koenig et al.38 Highest tertile (median, 10.6 μg/mL) vs lowest (3.8 μg/mL) Multivariable 0.55 0.35, 0.89
Age, BMI, smoking, alcohol intake, physical activity, hypertension, history of 
myocardial infarction
Model 2 0.81 0.50, 1.33 Additional adjustment for HDL-C
Nakashima 
et al.62
Highest tertile (median, 17.4 μg/mL) vs 
lowest (5.4 μg/mL) Multivariable 0.56 0.32, 0.99 Age, sex, BMI, waist-hip ratio, HOMA-IR, glucose tolerance classification
Snijder et al.28 Highest quartile (median, 28.4 μg/mL in 
men, 24.8 μg/mL in women) vs lowest 
(8.1 μg/mL in men, 8.5 μg/mL in women)
Multivariable 0.43 0.19, 0.94 Age, waist-hip ratio, smoking, performance of sports, leptin
Model 2 0.72 0.36, 1.42 Additional adjustment for fasting and 2-h glucose
Model 3 0.75 0.38, 1.51 Additional adjustment for TG
Wannamethee 
et al.32 Highest tertile (median, 13.7 μg/mL) vs 
lowest (3.6 μg/mL)
Multivariable 0.40 0.23, 0.70
Age, BMI, social class, physical activity, smoking, alcohol intake, history of 
coronary heart disease or stroke, statin use, blood pressure, treatment for 
hypertension
Model 2 0.59 0.33, 1.04 Additional adjustment for HOMA-IR
Model 3 0.67 0.38, 1.20 Additional adjustment for HDL-C and CRP
Heidermann 
et al.27
Highest quintile (median, 28.4 μg/mL) vs 
lowest (8.1 μg/mL) Multivariable 0.17 0.12, 0.25
Age, BMI, ethnicity, physical activity, smoking, family history of diabetes, 
hormone therapy, alcohol intake, dietary factors. Matched for age at blood 
draw ( ± 1 year), date of blood draw ( ± 3 months), fasting status, race
Model 2 0.16 0.10, 0.27 Additional adjustment for hyperlipidemia, hypertension and CRP
Model 3 0.26 0.13, 0.51 Additional adjustment for fasting insulin
Ley et al.63 Per SD increment Multivariable 0.68 0.51, 0.90 age, sex, waist circumference, TG, HDL-C, hypertension, IGT
Mather et al.31 Per SD increment Multivariate 0.77 0.66, 0.89 age, sex, race/ethnicity
Model 2 0.84 0.71, 0.98 Additional adjustment for change in weight, change in adiponectin and baseline and change in insulinogenic index, 1/fasting insulin
Tábak et al.64 Per 1 μg/mL increment Multivariable 0.87 0.77, 0.97 Age, sex, BMI, physical activity, family history of diabetes, employment grade. Matched for matched on sex, age (5-year groups), and BMI (5 kg/m2 groups)
Model 2 0.89 0.79, 0.99 Age, sex, BMI, TC, TG, blood pressure
Model 3 0.89 0.79, 1.00 Additional adjustment for CRP
Model 4 0.94 0.82, 1.07 Additional adjustment for fasting glucose
Salomaa et al.6 Per SD increment Multivariable 0.67 0.61, 0.80
Sex, non-HDL-C, HDL-C, TG, BMI, systolic blood pressure, current 
smoking, blood glucose, history of cardiovascular disease event, use of 
antihypertensive medication
Per SD increment Multivariable 0.70 0.60, 0.90
Sex, non-HDL-C, HDL-C, TG, BMI, systolic blood pressure, current 
smoking, blood glucose, history of cardiovascular disease event, use of 
antihypertensive medication
Thorand et al.7
Highest tertile (median 13.3 μg/mL in men, 
18.1 μg/mL in women) vs. lowest tertile 
(6.7 μg/mL in men, 9.9 μg/mL in women)
Multivariable 0.28 0.20, 0.39 Age, sex, survey, BMI, smoking, alcohol consumption, physical activity
Model 2 0.38 0.27, 0.53
Additional adjustment for systolic blood pressure, TC/HDL-C, parental 
history of diabetes mellitus, CRP, interleukin-6, soluble ICAM-1 and soluble 
E-selection, and leptin
Zhu et al.8 Highest quartile (weighted median: 
10.61 μg/mL) vs. lowest (weighted median: 
3.48 μg/mL)
Multivariable 0.40 0.25, 0.64 Age, sex, ethnicity, center, hypertension, and parental history of diabetes, BMI, waist-to-hip ratio
Model 2 0.46 0.29, 0.74 Additional adjustment for inflammation score
Model 3 0.52 0.32, 0.85 Additional adjustment for fasting insulin
Model 4 0.82 0.48, 1.42 Additional adjustment for fasting glucose
Fagerberg et al.9 Highest tertile (18.28–40.78 μg/mL) vs lowest tertile (3.68–11.36 μg/mL) Multivariable 0.22 0.07, 0.69 HOMA-IR, AIR, smoking, IFG, IGT
Hanley et al.10 per SD increment Multivariable 0.67 0.46, 0.97 Age, sex, ethnicity, smoking, BMI
Model 2 0.64 0.43, 0.94 Age, sex, ethnicity, smoking, HDL-C
Model 3 0.69 0.49, 0.99 Age, sex, ethnicity, smoking, HOMA-IR
Model 4 0.81 0.56, 1.16 Age, sex, ethnicity, smoking, S1
Model 5 0.75 0.53, 1.06 Age, sex, ethnicity, smoking, IFG
Hivert et al.11 per SD increment Multivariable 0.57 0.40, 0.81 Age, sex, BMI
Model 2 0.58 0.41, 0.84 Additional adjustment for HOMA-IR
per SD increment Multivariable 0.53 0.39, 0.74 Age, sex, BMI
Continued
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for the validation study, but their main characteristics (age, sex, BMI etc.) were similar to those in the validation 
study43.
Body weight and height were self-reported at baseline and both follow-ups. BMI is calculated as weight (kilo-
grams) divided by height (meters) squared. For those with missing weight or height, BMI was calculated using 
imputed weight or height derived from the linear regression equation: Weight = y-intercept + gradient × height, 
Reference, Year Comparison Model RR 95% CI Adjustment for covariates
Model 2 0.69 0.51, 0.96 Additional adjustment for HOMA-IR, resistin, TNF-alpha
Montonen et al.12 Highest quintile (median 9.7 μg/mL in men, 
14.4 μg/mL in women) vs. lowest quintile 
(3.07 μg/mL in men, 4.74 μg/mL in women)
Multivariable 0.18 0.12, 0.28
Age, sex, education, sport activity, cycling, occupational activity, smoking, 
alcohol intake, consumptions of red meat, whole grain bread and coffee, BMI, 
waist-circumference
Model 2 0.26 0.16, 0.40 Additional adjustment for GGT, HDL-C, hs-CRP
Model 3 0.28 0.17, 0.44 Additional adjustment for HbA1c
Kizer et al.13 Highest quartile (median 23.6 μg/mL) vs. lowest (median 7.2 μg/mL) Multivariable 0.41 0.28, 0.61
Age, sex, race, income, smoking, alcohol, eGFR, prevalent congestive heart 
failure, prevalent atrial fibrillation, prevalent CHD, beta-blocker use, health 
status, BMI
Model 2 0.79 0.50, 1.23 Additional adjustment for systolic blood pressure, HDL-C, TG, CRP, HOMA-IR
Li et al.14 Highest quintile (median 13.9 μg/mL) vs. lowest quintile (median 4.3 μg/mL) Multivariable 0.72 0.42, 1.25
Age, sex, smoking, physical activity, alcohol consumption, family history of 
diabetes, BMI
Model 2 0.85 0.48, 1.49 Additional adjustment for CRP, fasting blood glucose, insulin
Lilja et al.15
Highest quartiles (≥12.1 μg/mL in men, 
≥18.4 μg/mL in women) vs. lowest quartile 
(≤6.2 μg/mL in men, ≤9.2 μg/mL in 
women)
Multivariable 0.40 0.30, 0.54 BMI
Model 2 0.49 0.35, 0.70
Additional adjustment for TC, hypertension, smoking, physical activity, 
university education, first-degree diabetes heredity, fasting and postload 
glucose
Model 3 0.55 0.38, 0.78 Additional adjustment for HOMA-IR
Marques-Vidal 
et al.16
Highest quartile (mean 17.3 μg/mL) vs. 
lowest quartile (mean 3.7 μg/mL)
Multivariable 0.41 0.26, 0.65 Age, gender, BMI
Model 2 0.64 0.40, 1.03
Additional adjustment for diabetes risk score (age, family history of type 
2 diabetes, height, waist circumference, resting heart rate, presence of 
hypertension, HDL-C, TG, fasting glucose and serum uric acid)
Kim et al.17 Highest tertil (≥6.23 μg/mL in men, 
≥9.47 μg/mL in women) vs. lowest tertile 
(<3.90 μg/mL in men, <6.01 μg/mL in 
women)
Multivariable 0.67 0.46, 0.96 Age, sex, BMI, waist circumferences
Model 2 0.67 0.45, 1.00 Additional adjustment for fasting serum glucose
Rubio-Martin 
et al.18
Highest tertile (>13.2 μg/mL) vs. lowest 
tertile (<6.6 μg/mL) Multivariable 0.24 0.07, 0.82 Age, sex, obesity, CRP
Sans et al.19 Per 1 log increase Multivariable 0.22 0.08, 0.61 Age, BMI, leptin
Model 2 0.25 0.09, 0.70 Age, BMI, insulin, years of school
Model 3 0.24 0.08, 0.72 Age, BMI, leptin, years of school, DBP, HDL-C, TG
Model 4 0.47 0.16, 1.40 Age, BMI, leptin, fasting glucose, years of school, DBP, HDL-C, TG
Julia et al.20 Highest tertile vs. lowest tertile Multivariable 0.56 0.27, 1.18 Age, sex, supplementation group, family history of diabetes and BMI. Matched for sex, age, BMI and initial supplementation group.
Model 2 0.71 0.33, 1.53 Additional adjustment for baseline glycaemia, TC and TG
Lindberg et al.21
Highest quartile (>10.35 μg/mL) vs. lowest 
quartile (≤5.13 μg/mL)
Multivariable 0.16 0.04, 0.66 Age and sex
Model 2 0.17 0.04, 0.75 Additional adjustment for hypertension, hypercholesterolemia, current smoking, previous MI, BMI, blood glucose
Model 3 0.15 0.02, 0.90 Additional adjustment for TC, HDL-C, LDL-C, TG
Yamamoto et al.22 Highest quartile (≥9.6 μg/mL) vs. lowest (<5.2 μg/mL) Multivariable 0.40 0.25, 0.64 Age, sex, family history, smoking, alcohol drinking, physical activity, BMI
Model 2 0.53 0.33, 0.86 Additional adjustment for HOMA-IR
Model 3 0.56 0.35, 0.91 Age, sex, family history, smoking, alcohol drinking, physical activity, BMI, HbA1c
Model 4 0.69 0.42, 1.13 Additional adjustment for HOMA-IR
Neville et al.23 Highest tertile (>6.66 μg/mL) vs. lowest (<3.77 μg/mL) Multivariable 0.29 0.17, 0.52
Age, BMI, waist/hip ratio, alcohol status, smoking status, measures of 
socioeconomic status (includes material conditions and deprivation score), 
physical activity
Model 2 0.37 0.20, 0.67 Additional adjustment for TC, HDL-C, TG, systolic blood pressure, on drug treatment for hypertension, CRP
Model 3 0.54 0.29, 0.99 Additional adjustment for HOMA-IR
Table 4. Results of the 33 prospective studies included in the meta-analysis. Abbreviations: OR, odds ratio; CI, 
confidence interval; TNF-1, the tumour necrosis factor 1; PAI-1, plasminogen activator inhibitor 1; TC, total 
cholesterol; LDL-C, LDL cholesterol; HDL-C, HDL cholesterol; TG, triglycerides; TG/HDL-C, the ratio of TG to 
HDL-C; CRP, C-reactive protein; hs-CRP, high-sensitivity CRP; IGT, impaired glucose tolerance; IFG, impaired 
fasting glucose; GGT, gamma-glutamyltransferase; ICAM-1, intercellular adhesion molecule 1; S1, insulin 
sensitivity index; eGFR, the epidermal growth factor receptor; CHD, coronary heart disease; DBP, diastolic 
blood pressure; MI, myocardial infarction.
www.nature.com/scientificreports/
9SCiENTifiC RePoRts |  (2018) 8:406  | DOI:10.1038/s41598-017-18709-9
where values for the y-intercept and gradient were derived from gender-specific weight-height regression lines 
obtained from all cohort participants with known heights and weights.
Establishment of nested case-control study. For the current analysis, we established a nested 
case-control study of 571 cases and 571 matched controls within this cohort. All cases and controls were free of 
physician-diagnosed T2D, cardiovascular disease and cancer at baseline interview as well as the time of blood col-
lection during 1999 and 2004. Cases were a total of 571 participants who subsequently reported to be diagnosed 
with incident T2D during follow-up II visit (2006–2010). Controls were chosen from the remaining participants 
who did not develop T2D or cardiovascular disease at follow-up II, and were matched for age (±3 years), date (±6 
months) of blood collection, sex and dialect group with the cases on a 1:1 ratio. Furthermore, the selected controls 
were screened for the presence of undiagnosed T2D at the time of blood donation by HbA1c measurements. All 
matched controls with HbA1c ≥6.0% (42 mmol/mol) were considered ineligible for the study and a replacement 
control with the same matching criteria was randomly chosen among the remaining eligible subjects.
Laboratory procedures. Random morning peripheral blood samples were obtained, and frozen plasma 
aliquots from the cases and controls were analyzed simultaneously in the same batch at the National University 
Hospital Reference Laboratory, Singapore. Adiponectin levels were measured by ELISA/Evolis (Bio-Rad 
Laboratories, Hercules, CA). The within-assay and between-assay coefficients of variation were 3.9–5.9% and 
6.3–7.0%, respectively. Plasma hs-CRP levels and blood lipids (total cholesterol, TG and HDL-C) were measured 
via colorimetric method on a chemistry analyzer (AU5800 Analyzer, Beckman Coulter, Brea, CA). HbA1c was 
measured by HPLC method using Bio-Rad Variant II™ System (Bio-Rad Laboratories, Hercules, CA) in red 
blood cells.
Statistical analysis. Study participants were divided into tertiles and the lowest tertile served as the ref-
erence group. We used conditional logistic regression models to compute the OR and corresponding 95% CI 
between adiponectin and T2D with adjustment for age (continuous), education level (primary school and below, 
secondary or above), smoking status (never, ever smoker), alcohol consumption (never, ever drinker), weekly 
moderate-to-vigorous physical activity levels (<0.5, ≥0.5 hours/week), history of hypertension (yes, no), BMI 
(continuous), and tertiles of biomarkers, including the ratio of TG to HDL-C, hs-CRP, random glucose and ran-
dom insulin levels. We also calculated the T2D risk associated with per one log mg/L increment in adiponectin 
levels, in order to compare with previous studies5. To examine the impact of potential selection bias, we examined 
the adiponectin-T2D association among cases with HbA1c <6.5% or <6.0% and their matched controls. We 
stratified the analysis by sex, BMI, physical activity, smoking habits and hs-CRP level using unconditional logis-
tical regression models with additional adjustment for sex and dialect group, and we used restricted cubic spline 
regression with 3 knots at 25th, 50th and 75th percentiles of adiponectin concentrations to examine the linearity of 
adiponectin-T2D association.
The predictive utility of adiponectin was examined by establishing three logistic regression models. Base 
model 1 included education level, physical activity, history of hypertension, BMI, TG, HDL-C, and hs-CRP; 
base model 2 additionally included random glucose and insulin. Since previous studies have shown that HbA1c 
levels outperform glucose levels in predicting T2D44,45, we further established base model 3 to substitute random 
glucose from base model 2 with HbA1c levels. The improvement in discrimination was examined by comparing 
AUC between each base model and the model plus plasma adiponectin levels46. Moreover, due to the limitation 
of AUC such as its insensitivity to model improvement47, we also evaluated the category-free NRI and IDI48. The 
goodness-of-fit of all models were assessed by Akaike information criteria (AIC), where lower AICs indicate 
better model fit.
Meta-analysis. We performed an updated systematic review and meta-analysis of studies evaluating the 
association between adiponectin and T2D in adult populations since the date of the previous meta-analysis5. 
We followed the guidelines in Preferred Reporting Items for Systematic Reviews and Meta-Analyses and the 
Meta-analysis of Observational Studies in Epidemiology49. We searched systematically on PubMed for prospec-
tive human studies (including cohort, case-cohort, and nested case-control studies) assessing adiponectin-T2D 
associations between April 10, 2009 (the last date of literature research in the previous meta-analysis5) up to 
September 10, 2016. Our searches included both MeSH terms and key words without restrictions on language 
(Supplemental Material).
Studies were excluded if they were: (1) irrelevant (not using adiponectin as the exposure or T2D as the out-
come); (2) review, editorial, commentary, meta-analysis, animal or experimental study; (3) not prospective study 
(case-control, cross-sectional, and genetic studies). Identified studies were screened for titles and abstracts first, 
and then potentially relevant articles were reviewed for full-text (Supplementary Figure S2). Studies included 
in the previous meta-analysis5 were also reviewed for full-text and added into the current meta-analysis. Data 
extraction was conducted independently by 2 authors (Y.W., R.M.). Extracted information included study char-
acteristics (title, authors, publication year, study name, study design, follow-up length), participant characteristics 
(location, ethnic origin, sample size, number of incident T2D cases, gender composition, mean age or age range), 
adiponectin assay, T2D assessment, and analysis strategy (statistical models and covariates controlled). In case 
of multiple studies involving the same cohort, the most updated or relevant study was selected. We extracted 
relative risk estimates from the most fully-adjusted multivariable models. Studies qualities were assessed by the 
Newcastle-Ottawa Quality Assessment Scale50.
For the meta-analysis, RRs were used as the common measure of association, and ORs or hazard ratios (HRs) 
were considered as equivalent to RRs because of the low incident rate in most studies. To enhance consistency 
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Figure 2. The association between concentrations of adiponectin and type 2 diabetes in the updated meta-
analysis. The Solid line represents point estimates of relative risk for the adiponectin-diabetes association, and 
the dotted lines represent the upper and lower bound of 95% CIs. Cubic spline analysis was used to examine the 
association between adiponectin concentrations (categorical) and risk of developing type 2 diabetes using the most 
fully-adjusted models from reported studies. P = 0.33 for nonlinearity in the cubic spline regression model.
Figure 1. Adjusted relative risks of adiponectin levels with risk of type 2 diabetes in the updated meta-analysis. 
The summary estimates were obtained from the most fully-adjusted models of each study using a random-
effects model. The data markers indicate the adjusted relative risks (RRs) comparing extreme tertiles of 
adiponectin levels. The size of the data markers indicates the weight of the study, which is the inverse variance of 
the effect estimate. The diamond data markers indicate the pooled RRs.
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and improve comparability between studies, we transformed the originally reported RRs (per unit, per SD, per 
log increment, quartiles or quintiles) to a uniform comparison involving extreme tertiles of adiponectin levels 
using standard statistical methods which were described previously51,52. When RRs were reported in subgroups 
rather than the total sample in a study, a within-study RR was attained first using a fixed-effect analysis. RRs and 
corresponding 95% CIs were pooled by the DerSimonian-Laird random-effects models53, and fixed-effect models 
were used in sensitivity analyses. Between-study heterogeneity was evaluated by Cochran χ2 and I2 Statistic54. 
Meta-regression analyses were used to examine the influence of certain factors on observed associations, includ-
ing location, ethnicity, age, sex, follow-up duration, number of T2D cases, adiponectin assay, ascertainment of 
T2D, level of adjustment, and study quality. Stratified analyses were performed to evaluate the influences of base-
line participant characteristics on the results. Potential for publication bias was examined by Egger’s test55. To 
detect any nonlinear association, restricted cubic spline regression model with three knots at 25%, 50% and 
75% percentiles adiponectin distribution was applied. When the nonlinear hypothesis was rejected, a two-stage, 
log-linear, dose-response regression function was then used for both the fixed-effect and random-effect models to 
estimate the risk of T2D per 5 µg/mL increment in adiponectin levels56. Studies which reported case number, total 
number of participants, as well as adiponectin median value in each category were included in the dose-response 
meta-analysis. All P values were two-sided, and data were analyzed with STATA version 14 (Stata Corp, College 
Station, Texas).
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Conclusion
In conclusion, the strong, dose-dependent association between increased adiponectin levels and decreased T2D 
risk has been demonstrated in a Chinese population, and adiponectin may be a useful marker for T2D prediction 
among Chinese. Our meta-analysis strengthens the evidence that adiponectin is involved in T2D pathogenesis, 
and further clinical studies are needed to investigate the feasibility of targeting adiponectin through pharmaco-
logical, dietary and physical activity interventions to reduce the risk of T2D in high-risk population.
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